-
Rising Kenyan lakes push crocodiles closer to homes
-
Pacific islands alarmed by Trump-backed push for deep-sea mining
-
Istanbul cymbals: From Ottoman war tool to pulse of global music
-
Erratic rains dictate menu at three-star Michelin restaurant in Brazil
-
Myanmar ex-junta chief on first Thailand trip as civilian leader
-
Zverev, Auger-Aliassime and Medvedev exit Montreal Masters
-
Environmental disaster looms as tanker leaks off Oman
-
Google-parent Alphabet shakes up AI division
-
Embattled Infantino sees minnows Malawi reach WAFCON quarter-finals
-
FIFA back Infantino, apologise for World Cup privatisation plan
-
Seeds Rybakina, Pegula and Gauff advance at WTA Toronto event
-
Auger-Aliassime out of Montreal ATP event with injury
-
Zverev, Auger-Aliassime exit star-short Montreal Masters
-
Colombian baby hippo of Escobar stock dies after rescue
-
Embattled FIFA chief Infantino in emergency talks in Morocco
-
Preakness shifts 2027 dates to entice more Derby horses
-
Castaway SpaceX rocket stage crashed into Moon, scientists say
-
Guatemalan volcano eruption ends, locals return home
-
Dow edges to record as markets parse prospects for Hormuz deal
-
WHO chief urges stronger Ebola response in DR Congo visit
-
Salah arrives in Turkey to complete Trabzonspor move
-
Newcastle appoint Jaissle as new head coach after Howe exit
-
AFP journalist to be honored at International Press Freedom Awards
-
Swiss ski star Lara Gut-Behrami calls time on 18-year career
-
Turkish MPs back limited amnesty for Kurdish militants
-
US indicts leaders of Mexico's CJNG cartel, ups reward money
-
Noosha Aubel: Czy poradzi sobie z problemami Poczdamu?
-
Noosha Aubel: Klarar hon av Potsdams problem?
-
Noosha Aubel: Είναι σε θέση να αντιμετωπίσει τα προβλήματα του Πότσδαμ;
-
Noosha Aubel: Zvládne problémy Postupimi?
-
نوشا أوبيل: هل هي على مستوى التحديات التي تواجهها بوتسدام؟
-
Former England fly-half Burns retires from rugby union
-
Brazil hits new diplomatic lows with US and Argentina
-
Pakistan beat West Indies by eight wickets to level series
-
NZ boxer Parker promises ring return after doping ban 'lifted'
-
Reusser holds lead as Vollering wins in Tour de France hills
-
Disney profits top estimates on strength in theme park business
-
Argentina's Albornoz hit with four-game ban for 'intimidatory' referee abuse
-
LIV Golf CEO says funding secured to play beyond 2026
-
Guatemala volcano eruption eases off, but alert remains in place
-
Stocks stall tracking earnings, oil dips on Iran-Oman Hormuz move
-
Baby hippo descended from Escobar's herd rescued in Colombia
-
Tuipulotu to lead New Zealand in South African tour opener
-
Woman arrested after four men stabbed in central London
-
Leftist Democrat urges unity after victory in Michigan
-
Celtic boss O'Neill in hospital after 'small procedure'
-
Austria, Slovakia hit new temperature records
-
Israeli forces raid Palestinian refugee camp near Jerusalem
-
Where mountain lions roam, fewer deer in the headlights
-
Explosive drone found near Ukrainian plane at German airport
US panel weighs authorizing Covid vaccines for youngest children
After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.
Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.
Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."
Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.
Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.
They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.
But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.
There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.
Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.
Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."
E.Raimundo--PC